|
1
|
Anders C and Carey LA: Understanding and
treating triple-negative breast cancer. Oncology (Williston Park).
22:1233–1239; discussion 1239–1240, 1243. 2008.PubMed/NCBI
|
|
2
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hendrix MJ, Seftor EA, Hess AR and Seftor
RE: Vasculogenic mimicry and tumour-cell plasticity: Lessons from
melanoma. Nat Rev Cancer. 3:411–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paulis YWJ, Soetekouw PMMB, Verheul HMW,
Tjan-Heijnen VC and Griffioen AW: Signalling pathways in
vasculogenic mimicry. Biochim Biophys Acta. 1806:18–28.
2010.PubMed/NCBI
|
|
5
|
McDonald DM and Foss AJ: Endothelial cells
of tumor vessels: Abnormal but not absent. Cancer Metastasis Rev.
19:109–120. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sood AK, Seftor EA, Fletcher MS, Gardner
LM, Heidger PM, Buller RE, Seftor RE and Hendrix MJ: Molecular
determinants of ovarian cancer plasticity. Am J Pathol.
158:1279–1288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirakawa K, Kobayashi H, Heike Y,
Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M
and Wakasugi H: Hemodynamics in vasculogenic mimicry and
angiogenesis of inflammatory breast cancer xenograft. Cancer Res.
62:560–566. 2002.PubMed/NCBI
|
|
8
|
Sharma N, Seftor RE, Seftor EA, Gruman LM,
Heidger PM Jr, Cohen MB, Lubaroff DM and Hendrix MJ: Prostatic
tumor cell plasticity involves cooperative interactions of distinct
phenotypic subpopulations: Role in vasculogenic mimicry. Prostate.
50:189–201. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hao X, Sun B, Zhang S and Zhao X:
Microarray study of vasculogenic mimicry in bi-directional
differentiation malignant tumor. Zhonghua Yi Xue Za Zhi.
82:1298–1302. 2002.(In Chinese). PubMed/NCBI
|
|
10
|
Dupuy E, Hainaud P, Villemain A,
Bodevin-Phèdre E, Brouland JP, Briand P and Tobelem G: Tumoral
angiogenesis and tissue factor expression during hepatocellular
carcinoma progression in a transgenic mouse model. J Hepatol.
38:793–802. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q,
Dong X, Li J, Liu F, Jia X, et al: Twist1 expression induced by
sunitinib accelerates tumor cell vasculogenic mimicry by increasing
the population of CD133+ cells in triple-negative breast cancer.
Mol Cancer. 13:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shook D and Keller R: Mechanisms,
mechanics and function of epithelial-mesenchymal transitions in
early development. Mech Dev. 120:1351–1383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Z, Sun B, Qi L, Li H, Gao J and Leng
X: Zinc finger E-box binding homeobox 1 promotes vasculogenic
mimicry in colorectal cancer through induction of
epithelial-to-mesenchymal transition. Cancer Sci. 103:813–820.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang L, Du WW, Yang W, Rutnam ZJ, Peng C,
Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, et al: MiR-93
enhances angiogenesis and metastasis by targeting LATS2. Cell
Cycle. 11:4352–4365. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X,
Zhou C and Jiao D: Identification of microRNA-93 as a functional
dysregulated miRNA in triple-negative breast cancer. Tumour Biol.
36:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S, Chen X, Sun KX, Xiu YL, Liu BL,
Feng MX, Sang XB and Zhao Y: MicroRNA-93 promotes
epithelial-mesenchymal transition of endometrial carcinoma cells.
PLoS One. 11:e01657762016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shyamasundar S, Lim JP, Bay BH and SUKANYA
S: miR-93 inhibits the invasive potential of triple-negative breast
cancer cells in vitro via protein kinase WNK1. Int J Oncol.
49:2629–2636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim YK, Yu J, Han TS, Park SY, Namkoong B,
Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, et al: Functional links
between clustered microRNAs: Suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res.
37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li W, Liang L, He X, Wan D and Gu J: Study
on the mechanism of hsa-miR93 in liver cancer. Weichangbingxue he
Ganbingxue Zazhi. 17:478–480. 2008.(in Chinese).
|
|
24
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lowery AJ, Miller N, Devaney A, McNeill
RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, et
al: MicroRNA signatures predict oestrogen receptor, progesterone
receptor and HER2/neu receptor status in breast cancer. Breast
Cancer Res. 11:478–480. 2009. View
Article : Google Scholar
|
|
26
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao X, Hu J and Zhao X: Screening of
differentially expressed miRNA in triple negative breast cancer.
Jiaotong University Xuebao. 5:569–571. 2012.(in Chinese).
|
|
29
|
Zhao X, Hu J and Zhao X: Expression and
significance of hsa-miR-93 in triple negative breast cancer.
Zhonghua Linchuang Yishi Zazhi. 6:3914–3916. 2012.
|
|
30
|
Weng C, Dong H, Chen G, Zhai Y, Bai R, Hu
H, Lu L and Xu Z: miR-409-3p inhibits HT1080 cell proliferation,
vascularization and metastasis by targeting angiogenin. Cancer
Lett. 323:171–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang
Y, Cao S and Lin X: Role of microRNA-26b in glioma development and
its mediated regulation on EphA2. PLoS One. 6:e162642011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J,
King JA and Samant RS: Spheroid-forming subpopulation of breast
cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p
regulated de novo expression of osteopontin. J Cell Mol Med.
14((6B)): 1693–1706. 2010.PubMed/NCBI
|
|
33
|
Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW,
Che N, Wang XH, Du J, Liu YX and Sun BC: Expression and functional
significance of Twist1 in hepatocellular carcinoma: Its role in
vasculogenic mimicry. Hepatology. 51:545–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Plantamura I, Casalini P, Dugnani E, Sasso
M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli
C, Barajon I, et al: PDGFRβ and FGFR2 mediate endothelial cell
differentiation capability of triple negative breast carcinoma
cells. Mol Oncol. 8:968–981. 2014. View Article : Google Scholar : PubMed/NCBI
|
